Cerebrospinal News
-
How ReFlow Helped Get Zachary’s Hydrocephalus Under Control and Travel Across the Globe
Even before Zachary was born nearly 11 years ago, his parents Sherry and Jason knew that he was going to be a special boy – and a wonderful sibling to a twin sister! Zachary was born with spina bifida and hydrocephalus, both of which were diagnosed while in utero. As with many children in the hydrocephalus community, most parents have never heard of the condition, nor understand how it ...
-
Intermountain Primary Children’s Hospital First in Nation to Successfully Implant New Brain Shunt Accessory for Patients with Hydrocephalus
Surgeons at Intermountain Primary Children’s Hospital are the first in the nation to successfully implant a new brain shunt accessory for young patients with hydrocephalus, a neurological condition that causes a buildup of cerebrospinal fluid in the deep cavities of the brain that often causes frequent hospitalizations. This extra fluid puts pressure on the brain and can cause brain ...
-
Anuncia Releases User Guide Video for the ReFlow Mini Flusher
Step 1: Locate Locate the ReFlow Mini Flusher dome under the skin by touch. First, find the incision. Starting at the incision, trace toward the back of the head to find the flusher dome by touch. The ReFlow Mini Flusher dome will be located closest to the ventricular catheter and incision site. The valve is located after the flusher and should not be used for flushing. Step 2: Press Down ...
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid ...
-
7-year-old Boy Managing His Hydrocephalus with ReFlow Ventricular System “Gen 1” Featured on Charleston’s ABC News 4
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of ...
-
MDA Venture Philanthropy Grant to Support Development of ALS Biomarkers
The Muscular Dystrophy Association is pleased to announce the award of an MDA Venture Philanthropy (MVP) grant totaling $233,200 to Scottsdale, Ariz.-based Iron Horse Diagnostics to support development of a prognostic test for ALS (amyotrophic lateral sclerosis). Such a test could help improve and accelerate clinical trials and speed the development of life-saving drugs to people with ALS. MVP ...
By nVector
-
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
-
Anuncia Medical, Inc., receives FDA clearance for the ReFlow System Mini for the treatment of patients with hydrocephalus
Anuncia Medical, Inc., announced that the U.S. Food and Drug Administration (FDA) cleared the ReFlow® System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid (CSF) disorders that require shunting. Anuncia Medical announced FDA clearance of ReFlow® System Mini for the treatment of cerebrospinal fluid (CSF) disorders. The FDA 510(k) clearance allows ...
-
LaunchPad Medical Wins a $2.5 Million NIH Grant to Improve Cranial Procedures
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. The clinical use of this product is expected ...
By RevBio Inc.
-
Microbot Medical to Present the Self-Cleaning Shunt at the 16th Asian Australasian Congress of Neurological Surgeons
HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company’s Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel Neurosurgery Society and is being held from September 6th – 8th in Jerusalem, Israel. Dr Gustavo Rajz, Head of ...
-
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical data from its Phase 1/2a dose-escalation study of its clinical-stage candidate Temferon™ in patients with glioblastoma multiforme (GBM) who have an unmthylated MGMT gene promotor (uMGMT-GBM) at the ...
-
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD). Vaxxinity’s investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to treat PD and other ...
By Vaxxinit
-
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. Presentations will focus on the progression of Sangamo’s pre-clinical ...
-
Fonar Board of Directors Appoints Independent Director
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company´s board of directors and audit committee. Timothy Damadian, president and CEO of FONAR, said, “Our primary source of income and growth is attributable to FONAR’s ...
-
Fonar Announces First Fiscal Quarter Earnings
Total MRI scan volume at the HMCA-managed sites increased 11.6 % to 48,469 scans for the quarter ending September 30, 2021 versus the same quarter one year earlier. This is highest quarterly total in the Company’s history. Diluted Net Income per Common Share increased 53% to $0.55 for the quarter ended September 30, 2021 versus the same quarter one year earlier. Total Revenues-Net ...
-
Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis
Four separate research reports presented at premier Alzheimer’s disease and aging conferences add to the increasing set of details about the accuracy and clinical usefulness of the PrecivityAD™ blood test from C2N Diagnostics. The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the ...
-
Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research
Creative Proteomics, an integrated CRO company committed to providing a full range of services to support various proteome-related research projects from identification of single proteins to large-scale proteomic studies, has recently upgraded its fully-developed Exosome Proteomics Service to identify and quantify the proteins in exosomes. The company can also help discover biomarkers after ...
-
Anuncia Medical, Inc. Selects Scottsdale, Ariz. for New HQ to Further Develop Lifesaving Medtech
Anuncia Inc., a therapeutic medical device company and an emerging leader in cerebrospinal fluid (CSF) management innovation, announced today it is moving its headquarters to Scottsdale, Ariz. and will operate at SkySong, the Arizona State University Scottsdale Innovation Center. The move is the first geographic expansion for the high growth medtech startup previously based in Massachusetts. With ...
-
First Patient Treated in Polyganics’ ENCASE II Trial for Innovative Dura Sealant Patch, LIQOSEAL
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patient in its ENCASE II clinical trial for LIQOSEAL. LIQOSEAL is an easy-to-use, synthetic dura sealant patch indicated for use as an adjunct to standard methods of cranial dural repair, to provide watertight closure of the dura mater and ...
-
Anuncia ReFlow Tech Honored With Fast Company 2021 World Changing Ideas Awards
Anuncia Inc., an emerging leader in cerebrospinal fluid (CSF) management, received an Honorable Mention in the Health category of Fast Company’s 2021 World Changing Ideas Awards for its ReFlow™ medical device platform. Those honored were announced today by Fast Company and include businesses actively engaged and deeply committed to pursuing innovation aimed at solving health and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you